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THE WOMEN’S HEALTH INITIA-tive (WHI) trial of estrogenplusprogestin assessedwhether con-jugated equine estrogens (CEE)
plus medroxyprogesterone acetate
(MPA) prevents heart disease and hip
fractures and increases the risk of breast
cancer in 16 608 postmenopausal, pre-
dominantly healthy womenwith an in-
tact uterus who were 50 through 79
years old at study entry. Study out-
comes also included stroke, deep vein
thrombosis, pulmonary embolism, en-
dometrial cancer, colorectal cancer, hip,
vertebral andother fractures, death from
all causes, and a global index of benefit
and harm.
Although designed to yield appro-
priately powered risk estimates after 8
to 9 years, the trial was stopped at a
mean 5.6 years of follow-up because of
an increased risk of invasive breast can-
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Context TheWomen’s Health Initiative (WHI) trial of estrogen plus progestin vs pla-
cebowas stopped early, after a mean 5.6 years of follow-up, because the overall health
risks of hormone therapy exceeded its benefits.
Objective To report health outcomes at 3 years (mean 2.4 years of follow-up) after
the intervention was stopped.
Design, Setting, and Participants The intervention phase was a double-blind,
placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg
daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily, in 16 608 women aged
50 through 79 years, recruited by 40 centers from 1993 to 1998. The postinterven-
tion phase commenced July 8, 2002, and included 15 730 women.
Main Outcome Measures Semi-annual monitoring and outcomes ascertainment
continued per trial protocol. The primary end points were coronary heart disease and
invasive breast cancer. A global index summarizing the balance of risks and benefits
included the 2 primary end points plus stroke, pulmonary embolism, endometrial can-
cer, colorectal cancer, hip fracture, and death due to other causes.
Results The risk of cardiovascular events after the intervention was comparable by ini-
tial randomized assignments, 1.97% (annualized rate) in the CEE plusMPA (343 events)
and 1.91% in the placebo group (323 events). A greater risk of malignancies occurred in
theCEEplusMPA than in theplacebogroup (1.56%[n=281] vs 1.26%[n=218]; hazard
ratio [HR], 1.24; 95% confidence interval [CI], 1.04-1.48). More breast cancers were di-
agnosed inwomenwhohadbeen randomly assigned to receiveCEEplusMPAvsplacebo
(0.42%[n=79] vs 0.33%[n=60];HR, 1.27; 95%CI, 0.91-1.78)with amodest trend to-
warda lowerHRduring the follow-upafter the intervention.All-causemortalitywas some-
what higher in the CEE plus MPA than in the placebo group (1.20% [n=233] vs 1.06%
[n=196]; HR, 1.15; 95% CI, 0.95-1.39). The global index of risks and benefits was un-
changed fromrandomization throughMarch31,2005 (HR,1.12;95%CI,1.03-1.21), in-
dicating that the risks ofCEEplusMPAexceed thebenefits for chronic diseaseprevention.
Conclusions The increased cardiovascular risks in the women assigned to CEE plus
MPA during the intervention period were not observed after the intervention. A greater
risk of fatal and nonfatal malignancies occurred after the intervention in the CEE plus
MPA group and the global risk index was 12% higher in women randomly assigned
to receive CEE plus MPA compared with placebo.
Trial Registration clinicaltrials.gov Identifier: NCT00000611
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cer and the failure to demonstrate an
overall health benefit.1 Based on out-
comes adjudicated through a mean of
5.2 years of follow-up, women in the
CEE plus MPA group had higher risks
of cardiovascular disease (CVD), coro-
nary heart disease (CHD), stroke, ve-
nous thromboembolism, and breast
cancer and had lower risks of fracture
and colorectal cancer.Mortalitywas not
affected during the trial. Detailed in-
formation has since been provided for
the study outcomes ascertained during
the trial,2-11 guidelines for menopausal
hormone therapy have changed,12,13 and
prescriptions written have declined.14
This analysis, which includes adju-
dicated outcomes through the planned
trial duration of 8.5 years,was a planned
point of analysis to better understand
the changes in hormone-relevant health
conditions when postmenopausal hor-
mone therapy is stopped.We report the
health risks and benefits experienced
by 15730 trial participantswhohad fol-
low-up after the intervention from July
8, 2002, to March 31, 2005.
METHODS
Intervention Phase
Details of theWHI design have been re-
ported.15 Briefly, postmenopausal
women aged 50 through 79 years with
an intact uterus who gave written in-
formed consent were enrolled in the
WHI at 40 Clinical Centers in the
United States. A total of 16 608 eli-
gible women were randomly assigned
to receive active treatment (8506) or
placebo (8102) and were followed up
for an average of 5.6 years. Treatment
consisted of 0.625 mg of CEE, and 2.5
mg of MPA (Prempro, Wyeth Ayerst,
Philadelphia, Pennsylvania), ormatch-
ing placebo. At semiannual contacts in
the clinic or by telephone and at an-
nual visits to theWHI clinic, standard-
ized information was collected on
symptoms, adverse events, adherence
to study pills, and potential trial clini-
cal outcomes. Potential outcomes were
verified by obtaining medical records
and death certificates that were re-
viewed by physician adjudicators
blinded to treatment assignment.
Herein, the outcomes designated “clini-
cal trial or intervention phase” in-
clude outcomes adjudicated after the
analysis performed at 5.2 years and pre-
viously reported in the trial primary
outcomes article.1 Details regarding trial
exclusions and the protocol for ran-
domization, event ascertainment and
adjudication, study discontinuation,
and the calculation of the global index
have been reported.15 Race and ethnic-
itywere self-identified according to cat-
egories of the 1990 census. The proto-
col and consent forms were approved
by the institutional review boards at all
participating institutions.
Postintervention Phase
The period between the early termina-
tion of the intervention (July 7, 2002)
and the end of the predefined trial pe-
riod (March 31, 2005) defines the post-
intervention phase. Follow-up during
amean of 2.4 years accrued under strict
observance of the trial protocol for
semiannual end point ascertainment
and verification, aswell as annualmam-
mography surveillance.1,15
The postintervention phase in-
cludes events accrued through March
31, 2005, and adjudicated by Septem-
ber 30, 2005, at which point adjudica-
tion was 98% to 99% complete. From
randomization to July 7, 2002, 250
women died in the CEE plus MPA
group and 239 women in the placebo
group. Of 8506 women originally ran-
domized to CEE plus MPA, postinter-
vention information for the period July
8, 2002, to March 31, 2005, was avail-
able for 8052 women (95%). Of 8102
women randomized to placebo, post-
intervention information through
March 31, 2005, was available for 7678
(95%).
Statistical Analyses
Baseline characteristics of the women
in the CEE plus MPA and placebo
groups with any postintervention
information were compared by 2 or
t test. Annualized rates of events in
each treatment group were estimated
for the intervention phase, postinter-
vention phase, and overall by divid-
ing the number of events by the cor-
responding survival time in each
phase. The estimates for the clinical
trial–intervention phase, postinter-
vention phase, and overall (baseline
through March 30, 2005) apply the
time-to-event and intention-to-treat
methods previously used in the
analysis of the trial results.1 Hazard
ratios (HRs) were estimated from
Cox proportional hazards analyses
stratified by age, prior disease if
appropriate, and randomization
assignment in the dietary modifica-
tion trial. The beginning point of the
survival times (t=0) of the interven-
tion phase, postintervention phase,
and overall were defined to be the
date of randomization, date of trial
termination (July 7, 2002), and date
of randomization, respectively. P val-
ues are nominal and not adjusted for
sequential looks during the clinical
trial follow-up period.
We performed a formal test of
whether the HR in the clinical trial
phase equals the HR during the post-
intervention phase by defining a time-
dependent binary covariate, X(t), as
equal to 1 for participants taking CEE
plus MPA during the postintervention
period and 0 otherwise. The base-
line hazard functions were also
allowed to vary between trial phases.
The parametric portion of the esti-
mated log hazard function for the par-
ticipants taking CEE plus MPA is
then ^^X(t) with exp(^) equal to
the estimated HR during the clinical
trial phase and exp(^^) equal to the
estimated HR during the postinter-
vention phase. We tested whether ^
equals 0 and report the corresponding
P value, P difference.
We performed a sensitivity analysis
to assess the risks among women who
had been adherent to their study
medication (defined as 80%) during
the intervention phase of the trial. For
an appropriate comparison between
randomization groups, participants
adherent at the end of the interven-
tion phase were included in the post-
intervention HR estimation procedure
that used the inverse of the partici-
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pant’s estimated adherence probability
as a weighting factor. This method16
yields valid HR estimates among par-
ticipants meeting adherence criteria
provided that probabilities can be
accurately estimated. These probabili-
ties were estimated by logistic regres-
sion including the baseline variables
of age, ethnicity, education, body
mass index, smoking, self-reported
general health, night sweats, hot
flashes, breast tenderness, and treat-
ment assignment, and at year 1, breast
tenderness, night sweats, and hot
flashes. All analyses were performed
using SAS version 9.1.3 (SAS Institute
Inc, Cary, North Carolina).
RESULTS
Baseline Characteristics
Baseline demographic and risk factor
characteristics of the women with any
postintervention follow-up are shown
in TABLE 1. There were no statistically
significant differences between theCEE
plus MPA and placebo groups across
any of the 19 variables examined. Fol-
low-up during the postintervention
phase was missing for 389 of 15 730
participants (2.5%). Women with-
out postintervention follow-up did not
differ by treatment assignment (P=.63).
Clinical outcomes accrued during
the intervention phase and during
the posttrial follow-up are presented
by randomization assignment in
TABLE 2. Women with any postinter-
vention follow-up were included in
the analyses. Also shown in Table 2
are the events accumulated from ran-
domization to March 31, 2005 (mean
7.9 years of follow-up).
Postintervention Phase
The increased risks of CVD events in
women randomly assigned to CEE
plus MPA observed during the trial
were not observed in the postinter-
vention phase. During a mean 2.4
years of postintervention follow-up,
study participants had comparable
CVD event risks by initial randomized
assignments (HR, 1.04; 95% con-
fidence interval [CI], 0.89-1.21).
Among the individual cardiovascular
outcomes analyzed, all HRs were near
unity and none were statistically sig-
nificant. The increased risk of deep
vein thrombosis and pulmonary
embolism among women taking CEE
plus MPA vs placebo during the inter-
Table 1. Baseline Characteristics of Women’s Health Initiative Participants With Any
Postintervention Follow-up ( July 7, 2002-March 31, 2005)
No. (%) Alive in Follow-up
P Valuea
CEE  MPA
(n = 8052)
Placebo
(n = 7678)
Age at baseline, (mean, SD), y 63.1 (7.1) 63.3 (7.1) .21
Race/ethnicity
White 6788 (84.3) 6477 (84.4)
Black 517 (6.4) 533 (6.9)
Hispanic 426 (5.3) 385 (5.0) .56
American Indian 24 (0.3) 27 (0.4)
Asian/Pacific Islander 180 (2.2) 156 (2.0)
Unknown 117 (1.5) 100 (1.3)
Education
High school 5959 (74.4) 5580 (73.2) .09
BMI
25 2430 (30.3) 2373 (31.1)
25-30 2826 (35.3) 2689 (35.2) .48
30 2760 (34.4) 2568 (33.7)
Hypertension 2851 (38.5) 2772 (38.0) .51
Treated diabetes, pills or shots 344 (4.3) 321 (4.2) .78
Smoking status
Never smoked 4011 (50.3) 3823 (50.4)
Past smoker 3166 (39.7) 2990 (39.5) .93
Current smoker 794 (10.0) 765 (10.1)
Years since menopause
5 1268 (17.4) 1167 (16.4)
5-10 1405 (19.3) 1432 (20.1)
.30
10-15 1545 (21.2) 1494 (21.0)
15 3066 (42.1) 3027 (42.5)
Medical history
Myocardial infarction 126 (1.6) 136 (1.8) .31
Angina 290 (3.6) 302 (4.0) .28
Coronary revascularizationb 88 (1.1) 105 (1.4) .11
Stroke 55 (0.7) 64 (0.8) .28
DVT or PE 74 (0.9) 61 (0.8) .40
Breast cancer, female 1213 (15.9) 1110 (15.3) .29
Fracture 55 y 968 (14.1) 968 (14.3) .32
High cholesterol requiring pills 873 (12.2) 902 (12.7) .34
Baseline statin use 544 (6.8) 503 (6.6) .61
Baseline aspirin use, 80 mg/d 1535 (19.1) 1543 (20.1) .10
HT usage status
Never used 5929 (73.7) 5710 (74.4)
Past user 1589 (19.7) 1492 (19.4) .46
Current user 530 (6.6) 473 (6.2)
HT duration, y
5 1468 (69.1) 1394 (70.9)
5-10 405 (19.1) 329 (16.7) .14
10 250 (11.8) 244 (12.4)
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared;
CEE, conjugated equine estrogens; DVT, deep vein thrombosis, HT, hormone therapy; MPA, medroxyprogesterone
acetate; PE pulmonary embolism.
aTest of association between baseline characteristic and “Alive, in follow-up” for CEE plus MPA and placebo based on
2 or t test.
b Includes coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty.
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vention phase (HR, 1.98; 95% CI,
1.52-2.59) disappeared during the
postintervention period (HR, 0.95;
95% CI, 0.63-1.44).
In contrast, the annualized event
rates for the outcome “all cancer” was
higher during the postintervention fol-
low-up for the CEE plus MPA group
(1.56%per year) than the placebo group
(1.26% per year), with a correspond-
ingHR of 1.24 (95%CI, 1.04-1.48). Al-
though this reflects a greater risk of in-
vasive breast cancer in the CEE plus
MPA group (0.42% per year, n=79)
than in the group originally assigned to
placebo (0.33% year, n=60), the dif-
ference in risk was not statistically
significant (HR, 1.27; 95% CI, 0.91-
1.78). The rates of colorectal cancer
did not differ significantly between the
CEE plus MPA and placebo group.
Rates of endometrial cancer were lower
in the CEE plusMPA group than in the
group originally assigned to placebo
Table 2. Clinical Outcomes in the Women’s Health Initiative Conjugated Equine Estrogens Plus Medroxyprogesterone Acetate Trial and Its
3-Year Postintervention Follow-up
Outcomes
Events During Clinical Trial Phase
(n = 16608)a
Events During Postintervention Phase
(n = 15730)
P
Differ-
encee
Overall Combined Phases Datab
CEEMPA
(n = 8506)
Placebo
(n = 8102)
HR Ratio
(95% CI)c
CEEMPA
(n = 8052)
Placebo
(n = 7678)
HR
(95% CI)d
CEEMPA
(n = 8506)
Placebo
(n = 8102)
HR
(95% CI)d
No. of
Events
Annualized
Rates, %
No. of
Events
Annualized
Rates, %
No. of
Events
Annualized
Rates, %
No. of
Events
Annualized
Rates, %
No. of
Events
Annualized
Rates, %
No. of
Events
Annualized
Rates, %
Follow-up time,
mean mo
68.3 67.1 28.9 28.9 95.3 94.3
CVD
CHD 196 0.41 154 0.34 1.22
(0.99-1.51)
101 0.53 104 0.57 0.95
(0.73-1.26)
.15 297 0.45 258 0.41 1.11
(0.94-1.31)
CHD
death
40 0.08 36 0.08 1.04
(0.67-1.64)
32 0.17 33 0.18 0.96
(0.59-1.56)
.72 72 0.11 69 0.11 0.98
(0.71-1.37)
Total MI 168 0.35 127 0.28 1.26
(1.00-1.59)
80 0.42 79 0.43 0.99
(0.72-1.34)
.20 248 0.37 206 0.33 1.15
(0.96-1.39)
CABG/
PTCA
218 0.46 210 0.47 1.00
(0.82-1.21)
121 0.65 114 0.64 1.04
(0.81-1.35)
.80 339 0.51 324 0.52 1.01
(0.86-1.17)
Stroke 159 0.33 110 0.24 1.34
(1.05-1.71)
76 0.40 64 0.35 1.16
(0.83-1.61)
.48 235 0.35 174 0.28 1.28
(1.05-1.56)
DVT 122 0.26 61 0.14 1.88
(1.38-2.55)
34 0.18 31 0.17 1.07
(0.66-1.75)
.07 156 0.23 92 0.15 1.62
(1.25-2.09)
PE 87 0.18 41 0.09 1.98
(1.36-2.87)
27 0.14 24 0.13 1.07
(0.62-1.86)
.06 114 0.17 65 0.10 1.66
(1.22-2.25)
DVT/PE 168 0.35 79 0.18 1.98
(1.52-2.59)
44 0.23 45 0.25 0.95
(0.63-1.44)
.005 212 0.32 124 0.20 1.62
(1.30-2.03)
All CVD events 785 1.70 660 1.51 1.13
(1.02-1.25)
343 1.97 323 1.91 1.04
(0.89-1.21)
.37 1128 1.77 983 1.62 1.10
(1.01-1.20)
Cancer
Invasive
breast
206 0.43 153 0.34 1.26
(1.02-1.55)
79 0.42 60 0.33 1.27
(0.91-1.78)
.97 285 0.43 213 0.34 1.27
(1.06-1.51)
Endometrial 27 0.06 31 0.07 0.81
(0.48-1.35)
17 0.09 21 0.11 0.75
(0.40-1.43)
.83 44 0.07 52 0.08 0.78
(0.52-1.16)
Colorectal 50 0.10 75 0.17 0.62
(0.43-0.89)
34 0.18 30 0.16 1.08
(0.66-1.77)
.07 84 0.12 105 0.17 0.75
(0.57-1.00)
All cancer 606 1.29 548 1.25 1.03
(0.92-1.15)
281 1.56 218 1.26 1.24
(1.04-1.48)
.08 887 1.37 766 1.25 1.09
(0.99-1.20)
Fractures
Hip 53 0.11 75 0.17 0.67
(0.47-0.95)
54 0.28 57 0.31 0.92
(0.64-1.34)
.20 107 0.16 132 0.21 0.78
(0.60-1.00)
Vertebral 56 0.12 78 0.17 0.68
(0.48-0.96)
46 0.24 47 0.26 0.96
(0.64-1.44)
.23 102 0.15 125 0.20 0.78
(0.60-1.01)
Otherf 650 1.41 800 1.87 0.75
(0.68-0.83)
267 1.52 285 1.75 0.87
(0.74-1.03)
.16 917 1.44 1085 1.84 0.78
(0.72-0.85)
All fractures 741 1.61 903 2.12 0.76
(0.69-0.83)
337 1.95 346 2.16 0.91
(0.78-1.06)
.06 1078 1.70 1249 2.14 0.80
(0.73-0.86)
All-cause death 250 0.52 239 0.53 0.97
(0.81-1.16)
233 1.20 196 1.06 1.15
(0.95-1.39)
.27 483 0.71 435 0.68 1.04
(0.91-1.18)
Global index 876 1.89 736 1.68 1.12
(1.02-1.24)
468 2.67 415 2.44 1.11
(0.97-1.27)
.82 1344 2.10 1151 1.89 1.12
(1.03-1.21)
Abbreviations: CABG, coronary artery bypass graft; CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; DVT,
deep vein thrombosis; HR, hazard ratio; MI, myocardial infarction; MPA, medroxyprogesterone acetate; PE, pulmonary embolism; PTCA, percutaneous transluminal coronary angi-
oplasty.
a Includes all outcomes from randomization through July 7, 2002. The primary results for this trial were reported in Rossouw et al,1 which included outcomes adjudicated through data
closure at 5.2 years of follow up.
bData as of September 12, 2005; Events through March 31, 2005.
cFrom a proportional hazards model stratified by prevalent condition (where appropriate), age, and dietary modification randomization group. Time to event equals 0 on date of ran-
domization.
d From a proportional hazards model stratified by prevalent condition (where appropriate), age, and dietary modification randomization group. Time to event equals 0 on July 7,
2002.
eFrom a proportional hazards model stratified by prevalent condition (where appropriate), age, dietary modification randomization group, and trial phase (time-dependent). Time to
event equals 0 on date of randomization. Tests whether the HR for the trial phase equals the HR for the posttrial phase.
fOther osteoporotic fractures.
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(HR, 0.75; 95%CI, 0.40-1.43), but the
difference was not statist ical ly
significant.
Although women in the CEE plus
MPA group had a significantly lower
risk of fractures during the interven-
tion phase, differences by treatment
groupwere greatly attenuated after the
intervention (HR, 0.91; 95% CI, 0.78-
1.06). AllHRswere near unity andnone
were nominally statistically signifi-
cant.Osteoporotic fractures (other than
hip or vertebrae) had the smallest HR
of 0.87 (95% CI, 0.74-1.03). Post-
intervention mortality from all causes
was somewhat higher in women pre-
viously assigned toCEE plusMPA than
in those assigned to placebo (HR, 1.15;
95% CI, 0.95-1.39), a difference that
does not reach nominal statistical sig-
nificant.
Comparison of Intervention
and Postintervention Findings
The risk of CVD events in women as-
signed to CEE plus MPA decreased
from a HR of 1.13 (95%CI, 1.02-1.25)
during the intervention phase of the
trial to 1.04 (95% CI, 0.89-1.21) after
the intervention.However, a formal test
of whether the HRs in the preinterven-
tion and postintervention phases dif-
fer does not reach nominal signifi-
cance: P difference=.37. Cumulative
hazards of CHD are shown inFIGURE 1,
which presents Kaplan-Meier cumula-
tive hazards of each outcome from time
of randomization as well as from the
time of termination of the interven-
tion through the end of follow-up.
Figure 1 indicates that no excess risk
of CHD is apparent during the post-
intervention period for thewomen ran-
domized to CEE plus MPA.
The Kaplan-Meier cumulative haz-
ards for stroke reflects the overall 28%
excess risk of stroke throughMarch 31,
2005, for women assigned to CEE plus
MPA, anda smaller—not statistically sig-
nificant—excess risk of stroke (16%)
during the postintervention phase. The
estimatedHRs in thepreinterventionand
postintervention phases are not statisti-
cally significantly different (P differ-
ence =.48). The cumulative hazards in-
dicate that excess risk of pulmonary
embolism seen during the intervention
phase of the trial disappeared during the
postintervention period. Similar results
were seen for deep vein thrombosis (not
shown). The change in excess risk was
significant (P difference=.005) for the
combined endpoint of deep vein throm-
bosis and pulmonary embolism.
The HR for overall risk of all malig-
nancies increased from 1.03 (95% CI,
0.92-1.15) during the intervention
phase to 1.24 (95% CI, 1.04-1.48) in
the postintervention period (P differ-
ence=.08). During the intervention pe-
riod of the trial an excess risk of inva-
sive breast cancer with CEE plus MPA
use emerged with Kaplan-Meier esti-
mates of cumulative hazard compared
with placebo crossing in the fourth year
(HR, 1.26; 95% CI, 1.02-1.55). Al-
thoughmore breast cancers were diag-
nosed in theCEEplusMPA group (HR,
1.27; 95% CI, 0.91-1.78) after the in-
tervention, a downward inflection in the
temporal trend in cumulative HRs for
breast cancer was observed over time
(not shown), but the observed change
in HR after the intervention is not sta-
tistically significant.
The significantly lower colorectal
cancer risk observed in the CEE plus
MPA group during the intervention
phase did not persist after the inter-
vention, and the HR changed from
0.62 (95% CI, 0.43-0.89) to 1.08 (95%
CI, 0.66-1.77; P difference= .07). In
the postintervention period there were
34 and 30 colorectal cancers in the
active and placebo groups respectively
(Table 2), including 7 colorectal can-
cer deaths in the active treatment and
6 in the placebo group. The lower HR
for endometrial cancer in the active
and placebo groups observed during
the intervention phase (HR, 0.81; 95%
CI, 0 .48-1 .35) was e f fec t ive ly
unchanged during the postinterven-
tion follow-up.
The risk of fractures during the post-
intervention follow-up was compa-
rable among women in the CEE plus
MPA and placebo groups for each type
of fracture considered: hip, vertebral,
and other osteoporotic fractures. This
reflects a greater increase in the annu-
alized risk of fractures after the inter-
vention in thewomenwhohad been as-
signed toCEEplusMPAcomparedwith
women assigned to placebo, particu-
larly for hip and vertebral fractures.
Thus, the protective effects of CEE plus
MPApreviously evident during the trial
were not observed to carry over into the
postintervention phase: the HR for all
fractures increased from 0.76 (95%CI,
0.69-0.83) during the intervention
phase to 0.91 (95% CI, 0.78-1.06) af-
ter the intervention. The test of the dif-
ference in HRs for all fractures did not
reach nominal significance (P differ-
ence=.06). TheKaplan-Meier curves for
hip fracture suggest that the reduced
risk observed in the trial was dimin-
ished after the intervention, but the dif-
ference was not statistically signifi-
cant (P difference=.20).
During the intervention phase all-
cause mortality was almost identical in
both arms of the trial. During the post-
intervention phase, mortality from all
causes was higher by 15% in the group
originally assigned to CEE plus MPA
than in those assigned to placebo
(FIGURE2), although this differencewas
not statistically significant. The plots of
cumulative hazards of mortality sug-
gest a change in the temporal trends of
mortality prior to and following the ter-
mination of the intervention. The num-
ber of deaths in each of the prespeci-
fied trial outcome categories was small,
and they were very similar between the
2 groups. Most deaths were cancer re-
lated (101 in the CEE plusMPA group
vs 69 in the placebo group), thus ac-
counting for most of the difference in
mortality in thepostintervention follow-
up, but only 27 deaths in the CEE plus
MPA group and 16 deaths in the pla-
cebo groupwere associatedwith breast,
colorectal, endometrial, or ovarian can-
cer (prespecified cancer outcomes).
Thus, the other-cancers category ac-
counted for a larger absolute number
of deaths, but with a similar pattern of
association. Among the other cancers,
mostwere lung cancer events (33 in the
CEE plus MPA group vs 15 in the pla-
cebo group).
HEALTH RISKS AFTER STOPPING ESTROGEN AND PROGESTIN
1040 JAMA, March 5, 2008—Vol 299, No. 9 (Reprinted) ©2008 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of California - San Diego User  on 07/02/2019
Figure 1. Risks and Benefits by Randomized Assignment to Conjugated Equine Estrogens Plus Medroxyprogesterone Acetate or Placebo
Before and After Termination of the Intervention in the Women’s Health Initiative Estrogen Plus Progestin Trial
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Kaplan-Meier cumulative hazards for clinical outcomes by time in the trial and time after termination of intervention. The unshaded portion of the graphs identifies the
intervention period of 5.6 years. The shaded portion of the graphs represents the follow-up time after the intervention.
aOverall includes events from randomization to March 31, 2005.
bAfter intervention includes events from July 8, 2002, to March 31, 2005.
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The global index of risk vs benefit re-
mained essentially unchanged in the
postintervention period, maintaining a
nominally significant overall 12% in-
crease frombaseline throughMarch 31,
2005, for the women assigned to CEE
plus MPA (Figure 2).
At the time theWHI CEE plus MPA
trial was stopped, the mean follow-up
was 5.6 years (range, 3.5-8.5 years). At
that point, 58% of the women as-
signed to CEE plus MPA and 62% of
the women assigned to placebo were
taking their study pills.1 A sensitivity
analysis of the postintervention ef-
fects reported hereinwas conducted on
the study participants who had never
stopped participating, never took non-
study hormone therapy, and were ad-
herent at 80% or greater of studymedi-
cations through the trial stopping date
of July 7, 2002 (41% of those assigned
to active treatment and 47%of those as-
signed to placebo were available for
analysis). Among women adherent to
study medication, the HR and 95% CI
for the combined endpointswere as fol-
lows: all cardiovascular events, 1.05
(95% CI, 0.81-1.36); all cancers, 1.34
(95% CI, 1.02-1.76); fractures, 0.87
(95%CI, 0.69-1.10); and the global in-
dex, 1.19 (95% CI, 0.95-1.49). Thus,
although somewhat less precise, these
results are quite consistent with the es-
timated HRs for the entire group, with
the notable exception of an increased
risk of death from all causes during the
postintervention phase for adherers
originally assigned to active treatment
(HR, 1.53; 95% CI, 1.04-2.24) com-
pared with those assigned to placebo.
The corresponding cumulative, annu-
alizedmortality among adherers in the
active treatment and placebo groups are
0.82% and 0.61%, respectively.
COMMENT
Several patterns of health risks and ben-
efits associatedwith active treatment vs
placebo observed during theWHICEE
plus MPA trial were not maintained
during the postintervention phase from
July 8, 2002, toMarch 31, 2005.Within
3 years of cessation of the trial inter-
vention, both CVD risks and total and
hip fracture benefits dissipated, and
cancer risks increased. As a result, af-
ter a mean follow-up of 2.4 years after
the intervention, the overall assess-
ment of health risks and benefits asso-
ciated with CEE plus MPA continued
to be weighted toward risk, as sug-
gested by an adverse trend in all-cause
mortality and the global index.
The reductions in the risk of CVD re-
flect short-term temporal trends in the
risk of CHD, myocardial infarctions,
coronary revascularization proce-
dures, deep vein thrombosis, and pul-
monary embolism. Although the in-
creased risk of breast cancer appeared
to persist after the intervention, the re-
duced risk of colon cancer in the CEE
plus MPA group during the trial con-
verged toward the null during the post-
intervention phase. No differences in
the risk of fractures by treatment group
were apparent during the postinterven-
tion phase.Whereas mortality from all
causes did not differ by treatment dur-
ing the trial, a 15% greater mortality in
the group assigned to CEE plus MPA
was observed after the intervention, al-
though this difference did not reach
nominal statistical significance.
In a recent report by Ravdin and col-
leagues,17 age-adjusted breast cancer in-
cidence in the United States was re-
ported to have declined 6.7% in 2003, a
period in which prescriptions for hor-
Figure 2. Risk of Death From All Causes and Global Risk by Randomized Assignment to Conjugated Equine Estrogens Plus
Medroxyprogesterone Acetate or Placebo Before and After Termination of the Intervention in the Women’s Health Initiative Estrogen Plus
Progestin Trial
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Kaplan-Meier cumulative hazards for death and global risk index by time in the trial and time after termination of intervention. The unshaded portion of the graphs
identifies the intervention period of 5.6 years. The shaded portion of the graphs represents the follow-up time after the intervention.
aOverall includes events from randomization to March 31, 2005.
bAfter intervention includes events from July 8, 2002, to March 31, 2005.
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mone therapywereobserved todrop rap-
idly following the release of the WHI
CEEplusMPAtrial results.Although this
finding represents an ecological associa-
tion, it may reflect the large numbers of
womenwhoeitherdiscontinuedor failed
to initiatemenopausal hormone therapy
use. This decrease in breast cancer inci-
dence from mid-2002 to a lower pla-
teau after 2003was interpretedby the re-
port’s authors as most consistent with a
direct effect of hormone-replacement
therapy on preclinical disease,17 with-
out excluding contributions from tem-
poral changes in screeningmammogra-
phy18 and other factors.
Our results address onlywomenwho
stopped hormone therapy, with main-
tenance of annual mammography. The
trend of increasing risk of breast cancer
during the interventionphase of the trial
is seen not to extend beyond the termi-
nationof the intervention, butwe lacked
statistical power to identify a decrease in
breast cancer of the order of 9% to 10%,
such as that observed in the national
data.17 Further follow-up is needed to
characterize the risk of breast cancer in
theWHIpopulation.Thecurrently avail-
able information after the intervention
withCEEplusMPAis insufficient to sup-
port or refute any hypothesis regarding
the reported temporal decrease in breast
cancer incidence.
The juxtaposition of a randomized
controlled trial with an observational
postintervention phase warrants cau-
tion in the interpretation of our re-
sults. Although attribution of effects is
unequivocal in the former, any differ-
ences between the CEE plus MPA and
placebo groups seen during the post-
intervention phase could be attribut-
able to factors associated with, but not
inherent to the randomized treatment
regimens. For example, health care–
seeking behavior and cancer screen-
ing practices could have differed be-
tween the CEE plus MPA and placebo
groups after the trial was stopped and
the participants unblinded, although
this possibility is unlikely to have in-
fluenced rates of fatal events. It should
also be noted that annual mammogra-
phy screenings continued during the
postintervention phase and that com-
pleteness of follow-up was high and
comparable for the 2 groups.
Chance could have contributed to
some of our findings, consistent with
the relatively small numbers of events
available during thepostintervention in-
terval and the associated low preci-
sion for some of the estimates re-
ported herein. Further, at this stage the
cumulative hazards from time of ran-
domization are predominantly influ-
enced by the exposure time and event
rates accrued during the trial phase.
Conceivably, cessation of postmeno-
pausal hormone therapy could have
triggered adverse postintervention ef-
fects for one or another of the out-
comes reported herein. Considering
that newly diagnosedmalignancies and
cancer-related deaths are themain con-
tributors to the overall unfavorable pro-
file of postintervention health events,
such an interpretation seems implau-
sible. Instead, the trends over time in
risks during the intervention and post-
intervention periods support the inter-
pretation of the risks in the postinter-
vention period as cumulative or delayed
effects of the intervention.
The apparent excessmortality in the
CEEplusMPAvs the placebo group ob-
served during the postintervention
phase was accounted for by deaths at-
tributed to various cancers unrelated to
the prespecified trial outcomes, most
prominently lung cancers. Sex differ-
ences in lung cancer outcomehave been
reported, with women having de-
creased lung cancer survival com-
pared with men, adjusted for smoking
and comorbidities.19,20 Estrogen recep-
tors occur in non–small-cell lung can-
cer,21 and although results aremixed,22
menopausal hormone therapy use has
been found to be associated with sig-
nificantly decreased survival in women
with lung cancer in one recent re-
port23 and high estradiol levels were as-
sociated with poor lung cancer sur-
vival in another.24
There are similarities between our re-
sults and the pattern of fatal and nonfa-
tal noncardiovascular events reportedby
HERS II, the 2.7-year postintervention
follow-up of the Heart and Estrogen/
Progestin Replacement Study.25 Com-
paredwith the intervention phase in the
HERSstudy, the relativehazardsofbreast
cancer and colon cancer during the fol-
low-up converged toward the null,
whereas the relative hazards of lung can-
cer and any cancer increased in magni-
tude (and away from the null). A quali-
tativedifferencebetweenHERSII and the
postintervention phase of this trial is the
considerably higher use of CEE plus
MPA during the 2.7 years of the HERS
II follow-up(approximately50%in those
randomized to active treatment and ap-
proximately 6% for women random-
ized to placebo).25 Hormone therapyuse
8 to 12 months after stopping the WHI
trial was low among the women who
wereactively taking studypills at trial ter-
mination:4.3%inwomen formerly in the
CEEplusMPAcohort and1.2% in those
formerly taking placebo.26 The low
frequencyofhormone therapyuse1year
into the postintervention follow-up sug-
gests that hormone use at this time
did not influence the health risks and
benefits observed after stopping the
WHI CEE plusMPA trial to a meaning-
ful degree.
Implications
This analysis of delayed and sustained
health benefits and risks following ran-
domized allocation to CEE plus MPA
vs placebo adds new information to in-
form the optimal use of postmeno-
pausal CEE plusMPA. Over the course
of a mean 2.4 years from termination
of intervention with CEE plus MPA,
rapid changes in hormone therapy–
related risks and benefits were ob-
served, as well as trends that suggest
that continued follow-up of the study
participants of this trial will be infor-
mative as regards possible delayed ef-
fects of CEE plus MPA. During post-
intervention follow-up, the overall risk
of cardiovascular events was compa-
rable in those initially assigned to CEE
plusMPA and to placebo, a greater risk
of malignancies was observed in the
CEE plusMPA compared with the pla-
cebo group, and no differences in the
risk of fractures by treatment group
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were seen. Following termination of use
of CEE plus MPA of 3.5 to 8.5 years,
clinical vigilance seemswarrantedwith
respect to a sustained higher risk ofma-
lignancies.
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